Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| X4 Pharmaceuticals, IncXFOR · Entity 5638 | Chief Operating Officer | February 12, 2025 | February 14, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
X4 Pharmaceuticals, Inc
Report date February 12, 2025 · Filed February 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,140,980 |
Reported balance
After 2025-02-12 transaction · row 1
1 source rowRow 1 · 2025-02-12 · Grant · Acquired 650,000 · Balance 1,140,980 F1: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2025 Filed Feb 14, 2025 16:08 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 650,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-005696 · wk-form4_1739567286.xml · nonDerivative · entry 1 DiBiase Mary · CIK 0001880179 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,140,980 F1 · shares: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date. Read SEC document |
| January 24, 2025 Filed Jan 27, 2025 18:15 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 22,258 | $0.45 | $10,094.00 |
DisclosureSEC source: 0001628280-25-002706 · wk-form4_1738019716.xml · nonDerivative · entry 2 DiBiase Mary · CIK 0001880179 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 490,980 F2 · shares: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.4472 to $0.47, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 18:15 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 61,178 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-002706 · wk-form4_1738019716.xml · nonDerivative · entry 1 DiBiase Mary · CIK 0001880179 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 513,238 F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurred upon the acceptance by the European Medicines Agency of the Issuer's Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome. Read SEC document |
| October 07, 2024 Filed Oct 8, 2024 16:44 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 67,695 | $0.57 | $38,328.91 |
DisclosureSEC source: 0001628280-24-042542 · wk-form4_1728420247.xml · nonDerivative · entry 2 DiBiase Mary · CIK 0001880179 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 452,060 F2 · shares: These transactions were made pursuant to a rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.55 to $0.6043, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 16:44 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 230,645 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-042542 · wk-form4_1728420247.xml · nonDerivative · entry 1 DiBiase Mary · CIK 0001880179 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 519,755 F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 16:01 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 2,642 | $0.66 | $1,737.64 |
DisclosureSEC source: 0001628280-24-040128 · wk-form4_1726084882.xml · nonDerivative · entry 1 DiBiase Mary · CIK 0001880179 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 289,110 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.6548 to $0.6646, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · acquired: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award. Read SEC document |
| March 11, 2024 Filed Mar 11, 2024 17:19 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 15,409 | $0.88 | $13,590.74 |
DisclosureSEC source: 0001628280-24-010278 · wk-form4_1710191967.xml · nonDerivative · entry 1 DiBiase Mary · CIK 0001880179 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 291,752 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.863 to $0.91, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · acquired: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 17:09 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Appreciation Right · Derivative | 428,248 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001628280-24-005383 · wk-form4_1708121369.xml · derivative · entry 1 DiBiase Mary · CIK 0001880179 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 428,248 Underlying: Common Stock · 428,248 shares Expires 2034-02-13 F1 · derivative.exercise_date: The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date. Read SEC document |
| February 12, 2024 Filed Feb 12, 2024 17:23 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 3,683 | $1.01 | $3,708.78 |
DisclosureSEC source: 0001628280-24-004288 · wk-form4_1707776621.xml · nonDerivative · entry 1 DiBiase Mary · CIK 0001880179 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 307,161 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.98 to $1.04, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · acquired: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 16:40 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 67,695 | $0.73 | $49,417.35 |
DisclosureSEC source: 0001628280-23-036757 · wk-form4_1699044035.xml · nonDerivative · entry 1 DiBiase Mary · CIK 0001880179 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 310,844 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 2, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6839 to $0.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · acquired: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award Read SEC document |
| October 31, 2023 Filed Nov 2, 2023 16:55 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 230,645 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-036459 · wk-form4_1698958524.xml · nonDerivative · entry 1 DiBiase Mary · CIK 0001880179 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 378,539 F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor. Read SEC document |
| September 08, 2023 Filed Sep 12, 2023 16:04 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 2,642 | $1.25 | $3,299.86 |
DisclosureSEC source: 0001628280-23-032065 · wk-form4_1694549085.xml · nonDerivative · entry 1 DiBiase Mary · CIK 0001880179 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,894 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.22 to $1.255, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 74,046 shares represent restricted stock units. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 16:05 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 464 | $1.89 | $876.96 |
DisclosureSEC source: 0001628280-23-024229 · wk-form4_1688587495.xml · nonDerivative · entry 1 DiBiase Mary · CIK 0001880179 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,536 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.84 to $1.96, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 83,046 shares represent restricted stock units. Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 16:15 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 857 | $1.93 | $1,654.01 |
DisclosureSEC source: 0001628280-23-023445 · wk-form4_1687810523.xml · nonDerivative · entry 1 DiBiase Mary · CIK 0001880179 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,000 F1 · shares: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.90 to $1.96, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 84,624 shares represent restricted stock units. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 16:24 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 857 | $2.23 | $1,911.11 |
DisclosureSEC source: 0001628280-23-022480 · wk-form4_1686947049.xml · nonDerivative · entry 1 DiBiase Mary · CIK 0001880179 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,857 F1 · date: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $2.16 to $2.39, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 87,542 shares represent restricted stock units. Read SEC document |
| March 10, 2023 Filed Mar 13, 2023 16:52 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 18,192 | $0.84 | $15,281.28 |
DisclosureSEC source: 0001628280-23-007724 · wf-form4_167874073622856.xml · nonDerivative · entry 1 DiBiase Mary · CIK 0001880179 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,714 F1 · date: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $0.82 to $0.89, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 90,458 shares represent restricted stock units. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 17:13 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 4,348 | $0.93 | $4,043.64 |
DisclosureSEC source: 0001628280-23-003758 · wf-form4_167649918418679.xml · nonDerivative · entry 1 DiBiase Mary · CIK 0001880179 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,906 F1 · date: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $0.92 to $0.98, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 142,958 shares represent restricted stock units. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 16:23 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Appreciation Right · Derivative | 1,350,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001628280-22-029265 · wf-form4_166802896920270.xml · derivative · entry 1 DiBiase Mary · CIK 0001880179 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,350,000 Underlying: Common Stock · 1,350,000 shares Expires 2032-11-07 F1 · derivative.exercise_date: The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of November 7, 2022, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 13:07 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 1,713 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-023325 · wf-form4_166092881804874.xml · nonDerivative · entry 1 DiBiase Mary · CIK 0001880179 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,896 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.150 to $1.215, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 164,504 shares represent unvested restricted stock units. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 16:56 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 1,578 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-018397 · wf-form4_165670899460807.xml · nonDerivative · entry 1 DiBiase Mary · CIK 0001880179 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,609 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $0.88 to $0.92, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 170,338 shares represent unvested restricted stock units. Read SEC document |
| June 24, 2022 Filed Jun 27, 2022 16:09 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 856 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-018044 · wf-form4_165636053048715.xml · nonDerivative · entry 1 DiBiase Mary · CIK 0001880179 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,187 F1 · date: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · kind: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.06 to $1.11, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · balance_after: Of the shares of common stock reported, 171,916 shares represent unvested restricted stock units. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 16:21 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 856 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-017435 · wf-form4_165549727289558.xml · nonDerivative · entry 1 DiBiase Mary · CIK 0001880179 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,043 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.03 to $1.12 inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 174,832 shares represent unvested restricted stock units. Read SEC document |
| March 01, 2022 Filed Mar 1, 2022 16:16 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 105,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-004518 · wf-form4_164616936069234.xml · nonDerivative · entry 1 DiBiase Mary · CIK 0001880179 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,899 F1 · shares: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in two equal annual installments on March 1, 2023 and March 1, 2024, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date. F2 · balance_after: Of the shares of common stock reported, 177,748 shares represent unvested restricted stock units. Read SEC document |
| February 11, 2022 Filed Feb 14, 2022 16:22 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 12,545 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-002508 · wf-form4_164487367680982.xml · nonDerivative · entry 1 DiBiase Mary · CIK 0001880179 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,899 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.52 to $1.74, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 72,748 shares represent unvested restricted stock units. Read SEC document |
| September 08, 2021 Filed Sep 10, 2021 16:10 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-018385 · wf-form4_163130459114894.xml · nonDerivative · entry 1 DiBiase Mary · CIK 0001880179 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,444 F1 · shares: Represents restricted stock units issued to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer and has no expiration date. One third of the shares will vest on each of September 8, 2022, September 8, 2023 and September 8, 2024, respectively, subject to the Reporting Person providing continuous service to the Issuer on such dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.